Why McKesson (MCK) is a Top Momentum Stock for the Long-Term

McKesson (MCK), a leading North American pharmaceutical distributor, receives a #3 (Hold) rating from Zacks with a VGM Score of A. The stock shows strong momentum with a B score and 5.6% gains over four weeks. Analysts have raised fiscal 2027 earnings estimates by $0.18 to $44.73 per share, with GLP-1 medications driving growth at nearly $41 billion in FY25 revenues.